Why your medicine might be spinning: the hidden world of atropisomers
In short: Atropisomers are molecules that possess axial chirality, arising from hindered rotation around a single bond. While often dismissed as achiral in drug discovery, these molecules can bind to protein targets in highly specific ways. Understanding these dynamic structures is becoming a critical frontier in designing more effective, selective pharmaceuticals.
Atropisomerism is a form of axial chirality where rotation around a bond is restricted, creating distinct spatial arrangements. Unlike traditional chirality, which requires breaking and reforming bonds to change, atropisomers can interconvert through simple rotation. The stability of these forms depends on the energy barrier to rotation; when this barrier is high, the isomers can be isolated as stable, distinct entities. When the barrier is low, they rapidly interconvert at room temperature.
In the pharmaceutical industry, the standard approach has historically been to treat rapidly interconverting atropisomers as achiral. However, this is increasingly viewed as a missed opportunity. Research shows that even rapidly interconverting molecules often interact with proteins in an atroposelective manner, meaning one specific conformation may be far more effective than others. By synthesizing stable analogs, chemists can potentially lock a drug into its most potent configuration, improving its target profile and therapeutic efficacy.
The prevalence of these structures in medicine is significant. Approximately 15% of small-molecule drugs approved by the US FDA contain at least one atropisomeric axis, a figure that rises to 30% for drugs approved since 2011. Kinase inhibitors are particularly notable, with about 80% of FDA-approved versions possessing at least one rapidly interconverting axis. As the field matures, the ability to control these dynamic shapes is shifting from a technical challenge to a powerful tool for precision drug design.
Atropisomers are classified by their racemization barriers. Class 1 compounds racemize in minutes or less, while Class 3 compounds are stable for years, often serving as privileged scaffolds in catalysis or as essential natural products like vancomycin. By mapping the energy landscapes of these molecules, researchers are learning to manipulate their stereochemical stability, turning what was once considered a nuisance into a deliberate strategy for optimizing drug performance.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Atropisomerism in medicinal chemistry: challenges and opportunities
- Also: Atropisomer
To cite this card, link to https://intellectplus.co.uk/app/science-atropisomer.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Theory · More in Science · Latest · A–Z · All topics